Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020223306 - PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF

Publication Number WO/2020/223306
Publication Date 05.11.2020
International Application No. PCT/US2020/030405
International Filing Date 29.04.2020
IPC
C07D 487/16 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
12in which the condensed system contains three hetero rings
16Peri-condensed systems
C07D 487/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
22in which the condensed system contains four or more hetero rings
A61K 31/403 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
A61K 31/5377 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 471/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
22in which the condensed systems contains four or more hetero rings
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 487/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
C07D 491/147
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
12in which the condensed system contains three hetero rings
14Ortho-condensed systems
147the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Applicants
  • SNAP BIO, INC. [US]/[US]
Inventors
  • BURK, Mark J.
  • CHEN, Brandon
Agents
  • BUSSE, Paul, W.
  • BERGER, Scott, A.
  • BINDER, Mark, W.
  • BJORKMAN, Dale, A.
  • DAHL, Philip, Y.
  • D'SOUZA, Tanya, S.
  • HAKAMAKI, Michaele, A.
  • KAGAN, David, B.
  • PARINS, Paul, J.
  • SARAGENO, Lori, P.
  • SCHULTE, Daniel, C.
  • WEAVER, Paul, L.
  • WARNER, Elizabeth, A.
Priority Data
62/840,09529.04.2019US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF
(FR) COMPOSITIONS D'INHIBITEUR DE KINASE PIM ET UTILISATIONS ASSOCIÉES
Abstract
(EN) This disclosure relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.
(FR) La présente invention concerne des composés et des compositions utiles en tant qu'inhibiteurs de kinases PIM. L'invention concerne également des procédés de synthèse et des méthodes d'utilisation d'inhibiteurs de PIM dans le traitement d'individus souffrant de tumeurs malignes cancéreuses.
Related patent documents
US17607325This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau